Saturday 17 October 2026 Export SRRK’s income statement to Excel — free account

Scholar Rock Holding Corporation

Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million. In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 8.88% and total debt rose 294.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

39.85 0.79 −1.94%

Follow SRRK

Alert me

Market cap: $5.0B
P/E: 0.0×
Fwd P/E: −7.3×
Dividend yield: —
F-score: 3/9
Altman Z: 1.14
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 19.44

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	10	5	—	4	—	—	5	—	—	—

Insider Ownership 22.91%

Capital & Financial Ratios $m

Market Cap 4,950.00

Revenue 47.30

Net Income (408.59)

Free Cash Flow (297.01)

Net Debt (295.88)

Current Ratio 7.02

Debt/Equity 0.77

P/E ratio 0.00

Fwd P/E (7.27)

P/S ratio 110.04

P/B ratio 20.51

Past 5Y EPS Growth —

This Y EPS Growth (1.14%)

Next Y EPS Growth 22.33%

Next Y revenue growth (27.88%)

Next 5Y EPS Growth 26.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 88.58%

10-year low 10-year high

P/B against its own 10 years 86.81%

10-year low 10-year high

EV/Sales against its own 10 years 89.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	280	437	368	492
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	8	14	18	15
	288	451	385	507

	2023	2024	2025	Q'26
Payables	3	10	10	11
ST’ Debt	—	—	—	—
Other	0	—	—	—
	33	47	55	72

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	17.44%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(1.20%)	(1.93%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	33	—	—	—	33
’21	5	5	5	4	19
’20	5	4	3	3	15
’19	3	5	5	8	20

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(82)	(70)	—	—	—
’25	(79)	(77)	(69)	(75)	(300)
’24	(50)	(49)	(52)	(50)	(201)
’23	(43)	(33)	(32)	(37)	(145)
’22	(43)	(35)	(26)	(29)	(133)
’21	(27)	(32)	(36)	(32)	(127)
’20	3	(20)	(23)	(20)	(60)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(82)	(70)	—	—	—
’25	(79)	(77)	(69)	(76)	(301)
’24	(50)	(49)	(52)	(50)	(201)
’23	(43)	(33)	(32)	(37)	(145)
’22	(43)	(35)	(27)	(29)	(134)
’21	(29)	(33)	(37)	(33)	(132)
’20	2	(20)	(25)	(22)	(64)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.83)	(0.84)	—	—	—
’25	(0.67)	(0.98)	(0.90)	(0.88)	(3.29)
’24	(0.59)	(0.60)	(0.66)	(0.60)	(2.47)
’23	(0.49)	(0.47)	(0.53)	(0.50)	(1.99)
’22	(0.21)	(1.06)	(0.55)	(0.46)	(2.26)
’21	(0.76)	(0.84)	(1.02)	(0.97)	(3.59)
’20	(0.58)	(0.65)	(0.79)	(0.79)	(2.81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	13.09	6.95	9.23	21.84	4.33	5.56	6.76	22.71	Analyst estimates 2026–2028 Powerpack
	High	—	—	30.00	23.35	55.16	70.00	25.69	21.17	46.19	48.28
People
People	Employees	—	50	65	93	119	145	114	150	196	289
	Revenue/emp, $m	0.00	0.00	0.00	0.22	0.13	0.13	0.29	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	0	—	—	20	15	19	33	—	—	—
	Gross margin, %	100.00	0.00	0.00	100.00	100.00	100.00	100.00	—	—	—
	EBT	(16)	(25)	(49)	(51)	(86)	(132)	(135)	(166)	(246)	(378)
	EBT margin, %	(4,276.25)	0.00	0.00	(248.88)	(561.47)	(700.46)	(405.21)	0.00	0.00	0.00
	Net income	(16)	(25)	(49)	(51)	(86)	(132)	(135)	(166)	(246)	(378)
	Depreciation	0	1	0	0	1	4	2	(3)	(3)	(2)
Per share, $
Per share, $	Revenue	0.24	0.00	0.00	0.74	0.50	0.51	0.56	0.00	0.00	0.00
	Earnings	(10.11)	(15.30)	(3.15)	(1.85)	(2.81)	(3.59)	(2.26)	(1.99)	(2.47)	(3.29)
	Cash flow	(9.45)	(13.30)	1.57	(2.29)	(1.96)	(3.45)	(2.23)	(1.74)	(2.01)	(2.62)
	Capex	(0.50)	(0.22)	(0.10)	(0.11)	(0.13)	(0.14)	(0.02)	0.00	0.00	(0.01)
	Free cash flow	(9.94)	(13.52)	1.47	(2.40)	(2.09)	(3.60)	(2.24)	(1.74)	(2.01)	(2.62)
	Book value	17.49	34.09	6.81	4.10	8.48	4.69	4.37	2.70	3.69	2.14
	Shares, m	2	2	16	28	31	37	60	83	100	115
Valuation, ×
Valuation, ×	P/E	0.00	—	—	0.00	0.00	0.00	0.00	—	—	—
	P/S	0.00	—	—	17.71	96.83	48.47	12.07	—	—	—
	P/B	0.00	—	—	3.21	5.72	5.30	2.19	—	—	—
	EV/Sales	0.00	—	—	10.23	76.29	37.59	6.46	—	—	—
	EV/FCF	(0.51)	—	—	(3.17)	(18.26)	(5.36)	(2.28)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(15)	(22)	25	(63)	(60)	(127)	(133)	(145)	(201)	(300)
	Capex	(1)	0	(1)	(3)	(4)	(5)	(1)	0	0	(1)
	Free cash flow	(16)	(22)	23	(66)	(64)	(132)	(134)	(145)	(201)	(301)
Balance, $m
Balance, $m	Working capital	25	54	147	152	302	201	292	255	404	330
	Total debt	1	0	0	4	25	48	50	49	50	100
	Net debt	(27)	(58)	(176)	(153)	(316)	(205)	(266)	(231)	(387)	(268)
	Shareholders’ equity	28	56	107	113	261	172	260	225	369	245
Returns, %
Returns, %	ROA	(34.33)	(52.94)	(40.60)	(27.00)	(29.58)	(38.05)	(40.60)	(49.55)	(62.67)	(85.97)
	ROIC	(995.21)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	38.80	59.83	(185.78)	(46.46)	(46.29)	(60.90)	(62.22)	(68.30)	(82.95)	(123.08)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+48.17%	—	−23.34%	41.39%	0.00%

All 614 Biotechnology stocks →

Scholar Rock Holding Corporation (SRRK) key facts

Scholar Rock Holding Corporation (SRRK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
As of October 16, 2026, SRRK traded at $39.85, a market capitalization of $5.0 billion.
Return on equity was −123.1% and debt-to-equity 0.77.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.14 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.